OBJECTIVES/HYPOTHESIS: Human papillomavirus-16 (HPV-16)-associated carcinoma of the oropharynx has a favorable prognosis. Such patients have elevated CD8+ T-lymphocyte levels that correlate with response to chemotherapy and survival. Tumor-infiltrating lymphocyte (TIL) subpopulations were assessed in pretreatment biopsies from a prospective patient cohort to determine if TIL subsets differed by HPV status, clinical factors, or patient outcome or correlated with peripheral blood T-cell levels. STUDY DESIGN: Retrospective immunological correlative study of patients entered in a prospective Phase 2 clinical trial. METHODS: Measured were CD8, CD4, CD68, and Treg (FoxP3) lymphocytes by immunohistochemistry in a tissue microarray created from patients (n=46) with advanced oropharyngeal cancer. Correlations with peripheral blood levels, HPV status, expression of epidermal growth factor receptor (EGFR), clinical tumor, and patient characteristics and outcome were determined. Median follow-up was 6.6 years. RESULTS: HPV-16-positive patients had improved survival (P=.016). Degree of T-cell infiltration did not differ by HPV status but was significantly related to disease-specific survival (DSS) and overall survival (OS). Even after adjusting for HPV status, we found that CD8, FoxP3, and total T cells were significantly associated with DSS (P=.0236, P=.0040, and P=.0197, respectively) and OS (P=.0137, P=.0158, and P=.0115, respectively). Less T-cell infiltration (P=.0130) and CD4 cells in particular (P=.0792) were associated with higher EGFR expression. CONCLUSIONS: Improved outcomes are associated with increased TILs independent of HPV status and suggest the local immune response may be more related to factors such as tumor size, EGFR expression, or performance status than HPV status. Further study of larger numbers of patients and infiltrates combined with functional analysis of individual subsets may be necessary to detect significant differences in local immunity in HPV-16-related cancers.
OBJECTIVES/HYPOTHESIS: Human papillomavirus-16 (HPV-16)-associatedcarcinoma of the oropharynx has a favorable prognosis. Such patients have elevated CD8+ T-lymphocyte levels that correlate with response to chemotherapy and survival. Tumor-infiltrating lymphocyte (TIL) subpopulations were assessed in pretreatment biopsies from a prospective patient cohort to determine if TIL subsets differed by HPV status, clinical factors, or patient outcome or correlated with peripheral blood T-cell levels. STUDY DESIGN: Retrospective immunological correlative study of patients entered in a prospective Phase 2 clinical trial. METHODS: Measured were CD8, CD4, CD68, and Treg (FoxP3) lymphocytes by immunohistochemistry in a tissue microarray created from patients (n=46) with advanced oropharyngeal cancer. Correlations with peripheral blood levels, HPV status, expression of epidermal growth factor receptor (EGFR), clinical tumor, and patient characteristics and outcome were determined. Median follow-up was 6.6 years. RESULTS:HPV-16-positive patients had improved survival (P=.016). Degree of T-cell infiltration did not differ by HPV status but was significantly related to disease-specific survival (DSS) and overall survival (OS). Even after adjusting for HPV status, we found that CD8, FoxP3, and total T cells were significantly associated with DSS (P=.0236, P=.0040, and P=.0197, respectively) and OS (P=.0137, P=.0158, and P=.0115, respectively). Less T-cell infiltration (P=.0130) and CD4 cells in particular (P=.0792) were associated with higher EGFR expression. CONCLUSIONS: Improved outcomes are associated with increased TILs independent of HPV status and suggest the local immune response may be more related to factors such as tumor size, EGFR expression, or performance status than HPV status. Further study of larger numbers of patients and infiltrates combined with functional analysis of individual subsets may be necessary to detect significant differences in local immunity in HPV-16-related cancers.
Authors: Cécile Badoual; Stéphane Hans; José Rodriguez; Severine Peyrard; Christophe Klein; Nour El Houda Agueznay; Véronique Mosseri; Ollivier Laccourreye; Patrick Bruneval; Wolf H Fridman; Daniel F Brasnu; Eric Tartour Journal: Clin Cancer Res Date: 2006-01-15 Impact factor: 12.531
Authors: Derrick Wansom; Emily Light; Frank Worden; Mark Prince; Susan Urba; Douglas B Chepeha; Kitrina Cordell; Avraham Eisbruch; Jeremy Taylor; Nisha D'Silva; Jeffrey Moyer; Carol R Bradford; David Kurnit; Bhavna Kumar; Thomas E Carey; Gregory T Wolf Journal: Arch Otolaryngol Head Neck Surg Date: 2010-12
Authors: Abigail M Lee; Andrew J Clear; Maria Calaminici; Andrew J Davies; Suzanne Jordan; Finlay MacDougall; Janet Matthews; Andrew J Norton; John G Gribben; T Andrew Lister; Lindsey K Goff Journal: J Clin Oncol Date: 2006-10-10 Impact factor: 44.544
Authors: H Yang; K Yang; A Khafagi; Y Tang; T E Carey; A W Opipari; R Lieberman; P A Oeth; W Lancaster; H P Klinger; A O Kaseb; A Metwally; H Khaled; D M Kurnit Journal: Proc Natl Acad Sci U S A Date: 2005-05-24 Impact factor: 11.205
Authors: G T Wolf; S Schmaltz; J Hudson; H Robson; T Stackhouse; K A Peterson; J A Poore; K D McClatchey Journal: Arch Otolaryngol Head Neck Surg Date: 1987-11
Authors: Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos Journal: N Engl J Med Date: 2003-01-16 Impact factor: 91.245
Authors: Johannes A Veit; Daniela Heine; Julia Thierauf; Jochen Lennerz; Subasch Shetty; Patrick J Schuler; Theresa Whiteside; Dirk Beutner; Moritz Meyer; Inga Grünewald; Gerd Ritter; Sacha Gnjatic; Andrew G Sikora; Thomas K Hoffmann; Simon Laban Journal: Head Neck Date: 2016-02-13 Impact factor: 3.147
Authors: Gregory T Wolf; William Winter; Emily Bellile; Ariane Nguyen; C R Donnelly; Jonathan B McHugh; Dafydd Thomas; Lahin Amlani; Laura Rozek; Yu L Lei Journal: Oral Oncol Date: 2018-10-22 Impact factor: 5.337
Authors: Yu Lei; Yuying Xie; Yee Sun Tan; Mark E Prince; Jeffrey S Moyer; Jacques Nör; Gregory T Wolf Journal: Oral Oncol Date: 2016-08-21 Impact factor: 5.337
Authors: Rebecca Hoesli; Andrew C Birkeland; Andrew J Rosko; Mohamad Issa; Kelsey L Chow; Nicole L Michmerhuizen; Jacqueline E Mann; Steven B Chinn; Andrew G Shuman; Mark E Prince; Gregory T Wolf; Carol R Bradford; Jonathan B McHugh; J Chad Brenner; Matthew E Spector Journal: Oral Oncol Date: 2017-12-23 Impact factor: 5.337
Authors: Sweet Ping Ng; Houda Bahig; Amit Jethanandani; Courtney Pollard; Joel Berends; Erich M Sturgis; Faye M Johnson; Baher Elgohari; Hesham Elhalawani; David I Rosenthal; Heath D Skinner; G Brandon Gunn; Jack Phan; Steven J Frank; Abdallah S R Mohamed; Clifton D Fuller; Adam S Garden Journal: Radiother Oncol Date: 2020-01-10 Impact factor: 6.280
Authors: Silvana Papagerakis; Giuseppe Pannone; Li Zheng; Imad About; Nawar Taqi; Nghia P T Nguyen; Margarite Matossian; Blake McAlpin; Angela Santoro; Jonathan McHugh; Mark E Prince; Petros Papagerakis Journal: Exp Cell Res Date: 2014-05-05 Impact factor: 3.905
Authors: Rodney Macedo; Juliette Rochefort; Maude Guillot-Delost; Kae Tanaka; Aline Le Moignic; Clara Noizat; Claude Baillou; Véronique Mateo; Antoine F Carpentier; Eric Tartour; Chloé Bertolus; Bertrand Bellier; Géraldine Lescaille; François M Lemoine Journal: Oncoimmunology Date: 2016-07-06 Impact factor: 8.110